Comparative Pharmacology
Head-to-head clinical analysis: INNOFEM versus NOR QD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INNOFEM versus NOR QD.
INNOFEM vs NOR-QD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen receptor agonist; binds to estrogen receptors, leading to transcriptional activation of estrogen-responsive genes, promoting cellular proliferation in target tissues.
Progestin-only contraceptive; suppresses ovulation and alters cervical mucus and endometrium to inhibit sperm penetration and implantation.
2.5 mg orally once daily
0.35 mg orally once daily, taken at the same time each day.
None Documented
None Documented
10-15 hours (terminal) allowing twice-daily dosing; prolonged in hepatic impairment
Terminal elimination half-life (norethindrone) is 7-8 hours; clinical effect duration supports once-daily dosing.
Renal (approx. 80% as unchanged drug and metabolites), biliary/fecal (<5%)
Renal (approximately 30-50% as metabolites, <10% unchanged) and fecal (40-60% via biliary excretion); enterohepatic recirculation contributes to sustained levels.
Category C
Category C
Progestin Contraceptive
Progestin Contraceptive